JP2024522767A - 虚血再灌流傷害の処置または予防 - Google Patents

虚血再灌流傷害の処置または予防 Download PDF

Info

Publication number
JP2024522767A
JP2024522767A JP2023577694A JP2023577694A JP2024522767A JP 2024522767 A JP2024522767 A JP 2024522767A JP 2023577694 A JP2023577694 A JP 2023577694A JP 2023577694 A JP2023577694 A JP 2023577694A JP 2024522767 A JP2024522767 A JP 2024522767A
Authority
JP
Japan
Prior art keywords
composition
use according
salt
ischemia
reperfusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023577694A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024522767A5 (https=
JPWO2022263792A5 (https=
Inventor
クリーグ，トーマス
ピー マーフィー，マイケル
エイ プラグ，ハイラン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cambridge Enterprise Ltd
Original Assignee
Cambridge Enterprise Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Enterprise Ltd filed Critical Cambridge Enterprise Ltd
Publication of JP2024522767A publication Critical patent/JP2024522767A/ja
Publication of JP2024522767A5 publication Critical patent/JP2024522767A5/ja
Publication of JPWO2022263792A5 publication Critical patent/JPWO2022263792A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023577694A 2021-06-16 2022-06-08 虚血再灌流傷害の処置または予防 Pending JP2024522767A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2108594.9A GB202108594D0 (en) 2021-06-16 2021-06-16 Treatment or prevention of ischaemia reperfusion injury
GB2108594.9 2021-06-16
PCT/GB2022/051436 WO2022263792A1 (en) 2021-06-16 2022-06-08 Treatment or prevention of ischaemia reperfusion injury

Publications (3)

Publication Number Publication Date
JP2024522767A true JP2024522767A (ja) 2024-06-21
JP2024522767A5 JP2024522767A5 (https=) 2025-06-16
JPWO2022263792A5 JPWO2022263792A5 (https=) 2025-06-16

Family

ID=76954409

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023577694A Pending JP2024522767A (ja) 2021-06-16 2022-06-08 虚血再灌流傷害の処置または予防

Country Status (7)

Country Link
US (1) US20240252457A1 (https=)
EP (1) EP4355315A1 (https=)
JP (1) JP2024522767A (https=)
AU (1) AU2022294208A1 (https=)
CA (1) CA3222535A1 (https=)
GB (1) GB202108594D0 (https=)
WO (1) WO2022263792A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201918022D0 (en) * 2019-12-09 2020-01-22 Cambridge Entpr Ltd Treatment or prevention of Ischaemic Stroke Reperfusion Injury
WO2025125766A1 (en) 2023-12-12 2025-06-19 Cambridge Enterprise Limited Treatment or prevention of ischaemia reperfusion injury

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201411937D0 (en) * 2014-07-03 2014-08-20 Medical Res Council Succinate dehydrogenase inhibitors (SDH's)
EP3416634A4 (en) * 2016-02-15 2019-10-09 Artyomov, Maxim IMMUNOMODULATORY AGENTS AND METHOD FOR USE THEREOF
GB201918022D0 (en) * 2019-12-09 2020-01-22 Cambridge Entpr Ltd Treatment or prevention of Ischaemic Stroke Reperfusion Injury

Also Published As

Publication number Publication date
GB202108594D0 (en) 2021-07-28
CA3222535A1 (en) 2022-12-22
US20240252457A1 (en) 2024-08-01
WO2022263792A1 (en) 2022-12-22
EP4355315A1 (en) 2024-04-24
AU2022294208A1 (en) 2024-01-25

Similar Documents

Publication Publication Date Title
JP7364759B2 (ja) 酸素化コレステロール硫酸塩（ｏｃｓ）の使用
Kloner et al. New and revisited approaches to preserving the reperfused myocardium
JP2024522767A (ja) 虚血再灌流傷害の処置または予防
KR20170005497A (ko) 관상과 동맥의 동맥류성 지주하막출혈의 치료를 위한 조성물 및 방법
EP2782564B1 (en) Cysteamine and/or cystamine for treating ischemic injury
EP4072522B1 (en) Malonate salt for use in the treatment or prevention of ischaemic stroke reperfusion injury
JP2018508479A (ja) 虚血性脳卒中を予防・治療するための薬物の調製におけるビフェノールの使用
KR20180086431A (ko) L-오르니틴 페닐아세테이트의 제제
Wang et al. Direct visualization of microcirculation impairment after acute subdural hemorrhage in a novel animal model
AU2010277725B2 (en) Otamixaban for treatment of elderly and renal impaired non-ST elevation myocardial infarction patients
WO2025125766A1 (en) Treatment or prevention of ischaemia reperfusion injury
CN112755040B (zh) 果糖在制备治疗缺血性损伤药物中的应用
WO2009091134A2 (en) Pharmaceutical composition for sepsis and septic shock
EP4556472A1 (en) Use of pyridone derivative
US9597322B2 (en) Otamixaban for use in the treatment of non-ST elevation acute coronary syndrome in patients planned to undergo coronary artery bypass grafting
KR20090128479A (ko) 암 치료를 위한 경요도 절제술 후 방광내 아파지퀀 투여
WO2022199551A1 (en) Dc009 for treating acute ischemic stroke
US20210393585A1 (en) Method for preventing and/or treating a stress-induced disease
WO2019071171A1 (en) Method of treating sickle cell disease
Zoja et al. Models of human renal disease
JPWO2006035673A1 (ja) 虚血性心臓傷害の新保護法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250606

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250606

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260421